Abnormalities of aldosterone synthesis and action in children

Current Opinion in Pediatrics

Volumn 9, Issue 4, 1997, Pages 424-430

  White, Perrin C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ALDOSTERONE RECEPTOR; ELECTROLYTE; LIGAND; SODIUM CHANNEL;

BLOOD PRESSURE; CONGENITAL ADRENAL HYPERPLASIA; HOMEOSTASIS; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; HYPOALDOSTERONISM; HYPOKALEMIA; HYPONATREMIA; HYPOVOLEMIA; LIDDLE SYNDROME; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PSEUDOHYPOALDOSTERONISM; SHORT SURVEY;

EID: 0030775105     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199708000-00019     Document Type: Short Survey

References (51)

1. White PC: Disorders of aldosterone biosynthesis and action. N Engl J Med 1994, 331:250-258.
2. White PC: Genetic diseases of steroid metabolism. Vitam Horm 1994, 49:131-195.
3. Simard J, Durocher F, Mebarki F, Turgeon C, Sanchez R, Labrie Y, Couet J, Trudel C, Rheaume E, Morel Y: Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. J Endocrinol 1996, 150(Suppl):S189-207. Current review of the molecular biology of 3β-hydroxysteroid dehydrogenase and its deficiency.
4. Lin D, Sugawara T, Strauss JF, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL: Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995, 267:1828-1831.
5. Bose HS, Sugawara T, Strauss JF 3d, Miller WL: The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 1996, 335:1870-1878. Extends the findings of Lin et al. (Science 1995, 267:1828-1831) to 15 additional patients with lipoid adrenal hyperplasia who had mutations in the STAR protein. Some of the loss of steroidogenesis is due to damage of steroidogenic tissues by accumulated cholesterol esters.
6. Bose HS, Sugawara T, Strauss JF 3d, Miller WL: The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 1996, 335:1870-1878. Extends the findings of Lin et al. (Science 1995, 267:1828-1831) to 15 additional patients with lipoid adrenal hyperplasia who had mutations in the STAR protein. Some of the loss of steroidogenesis is due to damage of steroidogenic tissues by accumulated cholesterol esters.
7. Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992, 10:584-595.
8. Kohn B, Day D, Alemzadeh R, Enerio D, Patel SV, Pelczar JV, Speiser PW: Splicing mutation in CYP21 associated with delayed presentation of salt-wasting congenital adrenal hyperplasia. Am J Med Genet 1995, 57:450-454.
9. Witchel SF, Bhamidipati DK, Hoffman EP, Cohen JB: Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21 hydroxylase deficiency. J Clin Endocrinol Metab 1996, 81:4081-4088. Reports on asymptomatic persons with 21-hydroxylase deficiency who are apparently homozygous for a mutation in intron 2 of CYP21 that affects splicing. As discussed by Day et al. (Hum Mol Genet 1996, 5:2039-2048), these results may be typing artifacts.
10. Witchel SF, Bhamidipati DK, Hoffman EP, Cohen JB: Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21 hydroxylase deficiency. J Clin Endocrinol Metab 1996, 81:4081-4088. Reports on asymptomatic persons with 21-hydroxylase deficiency who are apparently homozygous for a mutation in intron 2 of CYP21 that affects splicing. As discussed by Day et al. (Hum Mol Genet 1996, 5:2039-2048), these results may be typing artifacts.
11. Day DJ, Speiser PW, Schultz E, Bettendorf M, Fitness J, Barany F, White PC: Identification of non amplifying CYP21 genes when using PCR-based diagnosis of 21 hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Hum Mol Genet 1996, 5:2039-2048. Analysis of complete kindreds is used to demonstrate that asymptomatic persons who are typed as homozygous for the intron 2 splicing mutation are only heterozygous carriers of this mutation, but the mutant allele is preferentially amplified by PCR.
12. Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestations. J Clin Endocrinol Metab 1994, 78:1145-1152.
13. Day D, Speiser PW, White PC, Barany F: Detection of steroid 21-hydroxylase alleles using a multiplexed ligation detection reaction and gene-specific PCR. Genomics 1995, 29:152-162.
14. White PC, Curnow KM, Pascoe L: Disorders of steroid 11 beta hydroxylase isozymes. Endocr Rev 1994, 15:421-438.
15. Ulick S, Wang JZ, Morton DH: The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. J Clin Endocrinol Metab 1992, 74:1415-1420.
16. Mitsuuchi Y, Kawamoto T, Miyahara K, Ulick S, Morton DH, Naiki Y, Kuribayashi I, Toda K, Hara T, Orii T, et al.: Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993, 190:864-869.
17. Geley S, Johrer K, Peter M, Denner K, Bernhardt R, Sippell WG, Kofler R: Amino acid substitution R384P in aldosterone synthase causes corticosterone methyloxidase type I deficiency. J Clin Endocrinol Metab 1995, 80:424-429.
18. Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC: Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A 1992, 89:4996-5000.
19. Zhang G, Rodriguez H, Fardella CE, Harris DA, Miller WL: Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency. Am J Hum Genet 1995, 57:1037-1043.
20. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP, McCabe ER: An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994, 372:635-641.
21. Luo X, Ikeda Y, Parker KL: A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994, 77:481-490.
22. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM: A chimaeric 11 beta hydroxylase/aldosterone synthase gene causes glucocorticoid remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
23. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC: Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 1992, 89:8327-8331.
24. Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez-Sanchez CE, Gasc JM, Saez JM, Corvol P: Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest 1995, 96:2236-2246.
25. Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L: The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol 1997, 4:32-35. Although CYP11B1 and CYP11B2 are only 93% identical in amino acid sequence, changing the two listed amino acid residues in CYP11B1 to the sequence of CYP11B2 is sufficient to confer 18-hydroxylase and 18-oxidase activity on CYP11B1.
26. Bottner B, Schrauber H, Bernhardt R: Engineering a mineralocorticoid to a glucocorticoid synthesizing cytochrome P450. J Biol Chem 1996, 271:8028-8033. This paper reports that converting Ala320 in CYP11B2 to Val destroys 18-oxidase activity and increases 11β-hydroxylase activity.
27. Dluhy RG, Lifton RP: Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995, 60:48-51.
28. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC, Connell JM: Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci 1995, 88:563-570.
29. Litchfield WR, Dluhy RG: Primary aldosteronism. Endocrinol Metab Clin North Am 1995, 24:593-612.
30. Abasiyanik A, Oran B, Kaymakci A, Yasar C, Caliskan U, Erkul I: Conn syndrome in a child, caused by adrenal adenoma. J Pediatr Surg 1996, 31:430-432. Aldosterone-producing adenomas are a rare cause of hyperaldosteronism in children.
31. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL: Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992, 19:319-322.
32. Carroll J, Dluhy R, Fallo F, Pistorello M, Bradwin G, Gomez-Sanchez CE, Mortensen R: Aldosterone producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. J Clin Endocrinol Metab 1996, 81:4310-4312. Whereas Pascoe et al. (J Clin Invest 1995, 96:2236-2246) report an adrenal adenoma in a patient with glucocorticoid-suppressible hyperaldosteronism, the converse is not usually true: gene arrangements of CYP11B1 and B2 were not detected in unselected aldosterone-producing adenomas.
33. Carroll J, Dluhy R, Fallo F, Pistorello M, Bradwin G, Gomez-Sanchez CE, Mortensen R: Aldosterone producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. J Clin Endocrinol Metab 1996, 81:4310-4312. Whereas Pascoe et al. (J Clin Invest 1995, 96:2236-2246) report an adrenal adenoma in a patient with glucocorticoid-suppressible hyperaldosteronism, the converse is not usually true: gene arrangements of CYP11B1 and B2 were not detected in unselected aldosterone-producing adenomas.
34. White PC, Mune T, Agarwal AK: 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997, 18:135-156. Recent review of this subject area.
35. Smith RE, MaGuire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fukushima K, Krozowski ZS: Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab 1996, 81:3244-3248. The type 2 or kidney isozyme is present in many mineralocorticoid-responsive epithelia, such as sweat and salivary glands.
36. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC: Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995, 10:394-399.
37. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI: A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995, 80:2263-2266.
38. Mune T, White PC: Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension 1996, 27:1193-1199. Biochemical phenotype in patients with AME, as measured by a precursor:product ratio, was correlated with the degree of enzymatic compromise conferred by the mutations in each patient.
39. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS: Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 1996, 119:21-24. Confirms the conclusions of Mune et al. (Nat Genet 1995, 10:394-399).
40. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS: Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 1996, 119:21-24. Confirms the conclusions of Mune et al. (Nat Genet 1995, 10:394-399).
41. Botero-Velez M, Curtis JJ, Warnock DG: Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
42. Shimkets RA, Warnock DG, Bositis CM, Nelson Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, et al.: Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
43. Schild L, Canessa CM, Shimkets RA, Gautschi I, Lifton RP, Rossier BC: A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci U S A 1995, 92:5699-5703.
44. Tamura H, Schild L, Enomoto N, Matsui N, Marumo F, Rossier BC: Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene. J Clin Invest 1996, 97:1780-1784. Missense mutations in a proline-rich region near the carboxyl terminus of the β subunit can constitutively activate the subunit.
45. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP: Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995, 11:76-82.
46. Kuhnle U, Hinkel GK, Akkurt HI, Krozowski Z: Familial pseudohypoaldosteronism: a review on the heterogeneity of the syndrome. Steroids 1995, 60:157-160.
47. Komesaroff PA, Verity K, Fuller PJ: Pseudohypoaldosteronism: molecular characterization of the mineralocorticoid receptor. J Clin Endocrinol Metab 1994, 79:27-31.
48. Zennaro MC, Borensztein P, Jeunemaitre X, Armanini D, Soubrier F: No alteration in the primary structure of the mineralocorticoid receptor in a family with pseudohypoaldosteronism. J Clin Endocrinol Metab 1994, 79:32-38.
49. Strautnieks SS, Thompson RJ, Hanukoglu A, Dillon MJ, Hanukoglu I, Kuhnle U, Seckl JR, Gardiner SM, Chung E: Localization of pseudohypoaldosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping. Hum Mol Genet 1996, 5:293-299. These chromosomal regions contain genes encoding the α and β subunits of the sodium channel.
50. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, et al.: Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253. An elegant study demonstrating that inactivating mutations in the α and β subunits of the sodium channel cause pseudohypoaldosteronism.
51. White PC: Steroid 11β-hydroxylase isozymes. Endocr Rev 1994, 15:423.